Skip to Content

Drug interactions between Plavix and Xtandi

Results for the following 2 drugs:
Plavix (clopidogrel)
Xtandi (enzalutamide)

Interactions between your drugs

Moderate

clopidogrel ↔ enzalutamide

Applies to:Plavix (clopidogrel) and Xtandi (enzalutamide)

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Coadministration with potent inhibitors of CYP450 2C8 may significantly increase the plasma concentrations of enzalutamide, which is primarily metabolized by the isoenzyme. In healthy volunteers, administration of a single 160 mg oral dose of enzalutamide following multiple oral doses of the potent CYP450 2C8 inhibitor gemfibrozil resulted in a 2.2-fold increase in the composite systemic exposure (AUC) of enzalutamide plus its pharmacologically active metabolite, N-desmethyl enzalutamide, compared to administration of enzalutamide alone. There was minimal effect on the peak plasma concentration (Cmax) of enzalutamide plus N-desmethyl enzalutamide.

MANAGEMENT: The use of enzalutamide in combination with potent CYP450 2C8 inhibitors such as gemfibrozil should generally be avoided. If concomitant use is required, a reduction of the enzalutamide dosage to 80 mg once daily is recommended. Following discontinuation of the potent CYP450 2C8 inhibitor, the enzalutamide dosage should be returned to that used prior to initiation of the inhibitor.

References

  1. "Product Information. Xtandi (enzalutamide)." Astellas Pharma US, Inc, Deerfield, IL.

Drug and food interactions

No results found in our database - however, this does not necessarily mean no interactions exist. Always consult with your doctor or pharmacist.

Therapeutic duplication warnings

No therapeutic duplications were found for your selected drugs.

Drug Interaction Classification

The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide